350 related articles for article (PubMed ID: 35215765)
1. Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication.
Fahnøe U; Pham LV; Fernandez-Antunez C; Costa R; Rivera-Rangel LR; Galli A; Feng S; Mikkelsen LS; Gottwein JM; Scheel TKH; Ramirez S; Bukh J
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215765
[TBL] [Abstract][Full Text] [Related]
2. Construction of a Noninfectious SARS-CoV-2 Replicon for Antiviral-Drug Testing and Gene Function Studies.
Nguyen HT; Falzarano D; Gerdts V; Liu Q
J Virol; 2021 Aug; 95(18):e0068721. PubMed ID: 34191580
[TBL] [Abstract][Full Text] [Related]
3. Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome.
Ye C; Chiem K; Park JG; Oladunni F; Platt RN; Anderson T; Almazan F; de la Torre JC; Martinez-Sobrido L
mBio; 2020 Sep; 11(5):. PubMed ID: 32978313
[TBL] [Abstract][Full Text] [Related]
4. A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
Zhang Y; Song W; Chen S; Yuan Z; Yi Z
Antiviral Res; 2021 Jan; 185():104974. PubMed ID: 33217430
[TBL] [Abstract][Full Text] [Related]
5. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.
He X; Quan S; Xu M; Rodriguez S; Goh SL; Wei J; Fridman A; Koeplinger KA; Carroll SS; Grobler JA; Espeseth AS; Olsen DB; Hazuda DJ; Wang D
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33766889
[TBL] [Abstract][Full Text] [Related]
6. Development of a Single-Cycle Infectious SARS-CoV-2 Virus Replicon Particle System for Use in Biosafety Level 2 Laboratories.
Malicoat J; Manivasagam S; Zuñiga S; Sola I; McCabe D; Rong L; Perlman S; Enjuanes L; Manicassamy B
J Virol; 2022 Feb; 96(3):e0183721. PubMed ID: 34851142
[TBL] [Abstract][Full Text] [Related]
7. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir.
Martin R; Li J; Parvangada A; Perry J; Cihlar T; Mo H; Porter D; Svarovskaia E
Antiviral Res; 2021 Apr; 188():105033. PubMed ID: 33549572
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 replicon for high-throughput antiviral screening.
Zhang QY; Deng CL; Liu J; Li JQ; Zhang HQ; Li N; Zhang YN; Li XD; Zhang B; Xu Y; Ye HQ
J Gen Virol; 2021 May; 102(5):. PubMed ID: 33956592
[TBL] [Abstract][Full Text] [Related]
9. A DNA-based non-infectious replicon system to study SARS-CoV-2 RNA synthesis.
Feng X; Zhang X; Jiang S; Tang Y; Cheng C; Krishna PA; Wang X; Dai J; Zeng J; Xia T; Zhao D
Comput Struct Biotechnol J; 2022; 20():5193-5202. PubMed ID: 36059866
[TBL] [Abstract][Full Text] [Related]
10. A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery.
Jin YY; Lin H; Cao L; Wu WC; Ji Y; Du L; Jiang Y; Xie Y; Tong K; Xing F; Zheng F; Shi M; Pan JA; Peng X; Guo D
Virol Sin; 2021 Oct; 36(5):913-923. PubMed ID: 33999369
[TBL] [Abstract][Full Text] [Related]
11. Bacterial Artificial Chromosome Reverse Genetics Approaches for SARS-CoV-2.
Chiem K; Nogales A; Almazán F; Ye C; Martínez-Sobrido L
Methods Mol Biol; 2024; 2733():133-153. PubMed ID: 38064031
[TBL] [Abstract][Full Text] [Related]
12. Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
Ramirez S; Fernandez-Antunez C; Galli A; Underwood A; Pham LV; Ryberg LA; Feng S; Pedersen MS; Mikkelsen LS; Belouzard S; Dubuisson J; Sølund C; Weis N; Gottwein JM; Fahnøe U; Bukh J
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0009721. PubMed ID: 33903110
[TBL] [Abstract][Full Text] [Related]
13. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M
Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962
[TBL] [Abstract][Full Text] [Related]
14. A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation.
Kotaki T; Xie X; Shi PY; Kameoka M
Sci Rep; 2021 Jan; 11(1):2229. PubMed ID: 33500537
[TBL] [Abstract][Full Text] [Related]
15. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.
Szemiel AM; Merits A; Orton RJ; MacLean OA; Pinto RM; Wickenhagen A; Lieber G; Turnbull ML; Wang S; Furnon W; Suarez NM; Mair D; da Silva Filipe A; Willett BJ; Wilson SJ; Patel AH; Thomson EC; Palmarini M; Kohl A; Stewart ME
PLoS Pathog; 2021 Sep; 17(9):e1009929. PubMed ID: 34534263
[TBL] [Abstract][Full Text] [Related]
16. Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors.
Luo Y; Yu F; Zhou M; Liu Y; Xia B; Zhang X; Liu J; Zhang J; Du Y; Li R; Wu L; Zhang X; Pan T; Guo D; Peng T; Zhang H
mBio; 2021 Jan; 12(1):. PubMed ID: 33468688
[TBL] [Abstract][Full Text] [Related]
17. Construction of Non-infectious SARS-CoV-2 Replicons and Their Application in Drug Evaluation.
Wang B; Zhang C; Lei X; Ren L; Zhao Z; Wang J; Huang H
Virol Sin; 2021 Oct; 36(5):890-900. PubMed ID: 33835389
[TBL] [Abstract][Full Text] [Related]
18. Reverse genetic systems of SARS-CoV-2 for antiviral research.
Kurhade C; Xie X; Shi PY
Antiviral Res; 2023 Feb; 210():105486. PubMed ID: 36657881
[TBL] [Abstract][Full Text] [Related]
19. Development of a Cell Culture Model for Inducible SARS-CoV-2 Replication.
Wang X; Zhu Y; Wu Q; Jiang N; Xie Y; Deng Q
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793589
[TBL] [Abstract][Full Text] [Related]
20. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
